MADRIGAL PHARMACEUTICALS, INC. Payments to Acquire Marketable Securities
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Payments to Acquire Marketable Securities of $359.55 million for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-06.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2023-11-06
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2023-09-30 was $68.85M, a 384.98% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2023-06-30 was $91.87M, a 16.40% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2023-03-31 was $198.82M, a 429.25% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire marketable securities for the quarter ending 2022-12-31 was $12.79M, a 76.65% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2022 was $143.48M, a 63.60% decline from fiscal 2021.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2021 was $394.12M, a 19.67% increase from fiscal 2020.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2020 was $329.34M, a 46.82% decline from fiscal 2019.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire marketable securities for fiscal 2019 was $619.30M, a 0.80% increase from fiscal 2018.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-09-30 | $68.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $160.73M derived: sum of 2 quarters · filed 2023-11-06 | $359.55M 10-Q · filed 2023-11-06 | $372.33M derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | $91.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $290.70M 10-Q · filed 2023-08-08 | $303.48M derived: sum of 3 quarters · filed 2023-08-08 | $317.68M derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-03-31 | $198.82M 10-Q · filed 2023-05-09 | $211.61M derived: sum of 2 quarters · filed 2023-05-09 | $225.80M derived: sum of 3 quarters · filed 2023-11-06 | $304.73M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-12-31 | $12.79M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | $26.98M derived: sum of 2 quarters · filed 2023-11-06 | $105.91M derived: sum of 3 quarters · filed 2023-11-06 | $143.48M 10-K/A · filed 2023-03-03 |
| 2022-09-30 | $14.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $93.13M derived: sum of 2 quarters · filed 2023-11-06 | $130.69M 10-Q · filed 2023-11-06 | $185.44M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $78.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $116.50M 10-Q · filed 2023-08-08 | $171.25M derived: sum of 3 quarters · filed 2023-08-08 | $286.55M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $37.57M 10-Q · filed 2023-05-09 | $92.32M derived: sum of 2 quarters · filed 2023-05-09 | $207.62M derived: sum of 3 quarters · filed 2023-05-09 | $337.96M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $54.75M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | $170.05M derived: sum of 2 quarters · filed 2023-03-03 | $300.40M derived: sum of 3 quarters · filed 2023-03-03 | $394.12M 10-K/A · filed 2023-03-03 |
| 2021-09-30 | $115.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $245.65M derived: sum of 2 quarters · filed 2022-11-03 | $339.37M 10-Q · filed 2022-11-03 | $455.53M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $130.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $224.07M 10-Q · filed 2022-08-04 | $340.23M derived: sum of 3 quarters · filed 2023-03-03 | $399.54M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | $93.72M 10-Q · filed 2022-05-09 | $209.88M derived: sum of 2 quarters · filed 2023-03-03 | $269.19M derived: sum of 3 quarters · filed 2023-03-03 | $364.42M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | $116.16M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-03-03 | $175.47M derived: sum of 2 quarters · filed 2023-03-03 | $270.69M derived: sum of 3 quarters · filed 2023-03-03 | $329.34M 10-K/A · filed 2023-03-03 |
| 2020-09-30 | $59.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $154.54M derived: sum of 2 quarters · filed 2021-11-04 | $213.19M 10-Q · filed 2021-11-04 | $425.42M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $95.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $153.87M 10-Q · filed 2021-08-05 | $366.10M derived: sum of 3 quarters · filed 2022-02-24 | $507.06M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $58.65M 10-Q · filed 2021-05-06 | $270.88M derived: sum of 2 quarters · filed 2022-02-24 | $411.83M derived: sum of 3 quarters · filed 2022-02-24 | $504.11M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $212.23M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $353.19M derived: sum of 2 quarters · filed 2022-02-24 | $445.47M derived: sum of 3 quarters · filed 2022-02-24 | $619.30M 10-K · filed 2022-02-24 |
| 2019-09-30 | $140.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $233.24M derived: sum of 2 quarters · filed 2020-11-05 | $407.07M 10-Q · filed 2020-11-05 | $496.50M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $92.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $266.12M 10-Q · filed 2020-08-06 | $355.54M derived: sum of 3 quarters · filed 2021-02-25 | $628.61M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $173.84M 10-Q · filed 2020-05-07 | $263.26M derived: sum of 2 quarters · filed 2021-02-25 | $536.33M derived: sum of 3 quarters · filed 2021-02-25 | $666.00M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $89.42M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $362.49M derived: sum of 2 quarters · filed 2021-02-25 | $492.17M derived: sum of 3 quarters · filed 2021-02-25 | $614.36M 10-K · filed 2021-02-25 |
| 2018-09-30 | $273.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $402.74M derived: sum of 2 quarters · filed 2019-11-06 | $524.93M 10-Q · filed 2019-11-06 | $560.24M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $129.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $251.87M 10-Q · filed 2019-08-07 | $287.17M derived: sum of 3 quarters · filed 2020-02-26 | $290.97M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $122.19M 10-Q · filed 2019-05-08 | $157.49M derived: sum of 2 quarters · filed 2020-02-26 | $161.29M derived: sum of 3 quarters · filed 2020-02-26 | |
| 2017-12-31 | $35.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $39.10M derived: sum of 2 quarters · filed 2020-02-26 | $70.21M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $34.91M 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $31.11M 10-Q · filed 2018-08-07 | |||
| 2016-12-31 | $10.70M 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |